Christmas has come early for Eli Lilly this year, courtesy of a fresh FDA approval for the Indianapolis drugmaker’s obesity ...

The OHG leadership shake-up comes amid a larger period of transition for Omnicom. In early December, the company laid out its ...

In this week’s episode of "The Top Line," we bring you a special conversation from earlier this month at our New York City ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

While Ionis has gained several FDA nods in its 35 years in existence, Tryngolza will be the first medicine the Carlsbad, ...

The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...

In a move that follows an increasingly common trend in biopharma M&A, Novartis is shedding sites and staffers from the German ...

Current treatments for chronic hand eczema (CHE) generally fall into two buckets: Either they battle inflammation but lead to ...

The data analytics and consulting company valued the market at $8.4 billion in 2021. The forecasted 7.4% compound annual ...

More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.

It’s not a new question, but it is one that is gaining increased traction: Is there a link between Novo Nordisk’s diabetes ...

Christmas seems to have come early for Klick Health, with a slew of new leaders arriving under the life sciences marketing ...